Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors

Dong Anh Khuong-Quang, Lauren M. Brown, Marie Wong, Chelsea Mayoh, Alexandra Sexton-Oates, Amit Kumar, Mark Pinese, Sumanth Nagabushan, Loretta Lau, Louise E. Ludlow, Andrew J. Gifford, Michael Rodriguez, Jayesh Desai, Stephen B. Fox, Michelle Haber, David S. Ziegler, Jordan R. Hansford, Glenn M. Marshall, Mark J. Cowley, Paul G. Ekert*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
4 Downloads (Pure)


The identification of rearrangements driving expression of neurotrophic receptor tyrosine kinase (NTRK) family kinases in tumors has become critically important because of the availability of effective, specific inhibitor drugs. Whole-genome sequencing (WGS) combined with RNA sequencing (RNA-seq) can identify novel and recurrent expressed fusions. Here we describe three SPECC1L–NTRK fusions identified in two pediatric central nervous system cancers and an extracranial solid tumor using WGS and RNA-seq. These fusions arose either through a simple balanced rearrangement or in the context of a complex chromoplexy event. We cloned the SPECC1L–NTRK2 fusion directly from a patient sample and showed that enforced expression of this fusion is sufficient to promote cytokine-independent survival and proliferation. Cells transformed by SPECC1L–NTRK2 expression are sensitive to a TRK inhibitor drug. We report here that SPECC1L–NTRK fusions can arise in a range of pediatric cancers. Although WGS and RNA-seq are not required to detect NTRK fusions, these techniques may be of benefit when NTRK fusions are not suspected on clinical grounds or not identified by other methods.

Original languageEnglish
Article numbera005710
Pages (from-to)1-17
Number of pages17
JournalCold Spring Harbor Molecular Case Studies
Issue number6
Publication statusPublished - Dec 2020
Externally publishedYes

Bibliographical note

Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


Dive into the research topics of 'Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors'. Together they form a unique fingerprint.

Cite this